Drug Type Antibody drug conjugate (ADC) |
Synonyms SHR 4602, SHR-4602, SHR4602 |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 18 Apr 2023 | |
HER2 Positive Solid Tumors | Phase 1 | CN | 18 Apr 2023 |